natgillin/translations-raw huggingface dataset:
Takový záznam může být přiřazen do jiné (i vyšší) kategorie nebo dokonce do jiné třídy nebezpečnosti, než je uvedeno.
The entry might be assigned to a different (also higher) category or even another hazard class than indicated.
Správná klasifikace musí být potvrzena pomocí zkoušek.
The correct classification shall be confirmed by testing.
Záznamy, u nichž je třeba potvrdit fyzikální nebezpečnost pomocí zkoušek, jsou v tabulce 3.1 označeny čtyřmi hvězdičkami (****).
The entries with physical hazards that need to be confirmed by testing are indicated by the reference **** in Table 3.1.
ČÁST 2: DOKUMENTACE K HARMONIZOVANÉ KLASIFIKACI A OZNAČOVÁNÍ
PART 2: DOSSIERS FOR HARMONISED CLASSIFICATION AND LABELLING
V této části jsou stanoveny všeobecné zásady přípravy dokumentace k návrhu a odůvodnění harmonizované klasifikace a označování.
This Part lays down general principles for preparing dossiers to propose and justify harmonised classification and labelling.
Na metodiku a formát veškeré dokumentace se použijí příslušné části oddílů 1, 2 a 3 přílohy I nařízení (ES) č. 1907/2006.
The relevant parts of sections 1, 2 and 3 of Annex I to Regulation (EC) No 1907/2006 shall be used for the methodology and format of any dossier.
Pro veškerou dokumentaci se zohlední všechny významné informace z dokumentací k registraci a lze využít i jiné dostupné informace.
For all dossiers any relevant information from registration dossiers shall be considered and other available information may be used.
Pokud jde o standardní věty o nebezpečnosti, které agentuře ještě nebyly předloženy, je nutné do dokumentace rovněž zahrnout podrobný souhrn studie.
For hazard information which has not been previously submitted to the Agency, a robust study summary shall be included in the dossier.
Dokumentace k harmonizované klasifikaci a označování obsahuje:
A dossier for harmonised classification and labelling shall contain the following:
Součástí návrhu je identifikace příslušné látky nebo látek a návrh na harmonizovanou klasifikaci a označování.
The proposal shall include the identity of the substance or substances concerned and the harmonised classification and labelling proposed.
Odůvodnění navrhované harmonizované klasifikace a označení
Justification for the proposed harmonised classification and labelling
Porovnání dostupných údajů s kritérii uvedenými v částech 2 až 5, při zohlednění obecných zásad uvedených v části 1 přílohy I tohoto nařízení, se vykoná a zaznamená ve formátu podle části B zprávy o chemické bezpečnosti v příloze I nařízení (ES) č. 1907/2006.
A comparison of the available information with the criteria contained in Parts 2 to 5, taking into account the general principles in Part 1, of Annex I to this Regulation shall be completed and documented in the format set out in Part B of the Chemical Safety Report in Annex I to Regulation (EC) No 1907/2006.
Odůvodnění pro jiné účinky na úrovni Společenství
Justification for other effects at Community level
Pro jiné účinky, než je karcinogenita, mutagenita, toxicita pro reprodukci a senzibilizace dýchacích cest, se uvede odůvodnění prokazující, že je nutné přijmout opatření na úrovni Společenství.
For other effects than carcinogenity, mutagenicity, reprotoxicity and respiratory sensitisation a justification shall be provided that there is a need for action demonstrated at Community level.
To neplatí pro aktivní látky ve smyslu směrnice 91/414/EHS nebo směrnice 98/8/ES.
This does not apply for an active substance in the meaning of Directive 91/414/EEC or Directive 98/8/EC.
ČÁST 3: TABULKY S HARMONIZOVANOU KLASIFIKACÍ A OZNAČOVÁNÍM
PART 3: HARMONISED CLASSIFICATION AND LABELLING TABLES
Tabulka 3.1: Seznam harmonizovaných klasifikací a označení nebezpečných látek je uveden v samostatném svazku IIIa.
Table 3.1: List of harmonised classification and labelling of hazardous substances is listed in the separate Volume IIIa.
Tabulka 3.2: Seznam harmonizovaných klasifikací a označení nebezpečných látek z přílohy I směrnice 67/548/EHS je uveden v samostatném svazku IIIb.
Table 3.2: The list of harmonised classification and labelling of hazardous substances from Annex I to Directive 67/548/EEC is listed in the separate Volume IIIb.
Tabulka 3.1
Table 3.1
Seznam harmonizovaných klasifikací a označení nebezpečných látek
List of harmonised classification and labelling of hazardous substances
Specifické koncent. limity, multiplikační faktory
Specific Conc. Limits, M-factors
Kódy tříd a kategorií nebezpečnosti
Hazard Class and Category Code(s)
Kódy standardních vět o nebezpečnosti
Hazard statement Code(s)
Kódy výstražných symbolů a signálních slov
Pictogram, Signal Word Code(s)
Kódy doplň. standardních vět o nebezpečnosti
Suppl. Hazard statement Code(s)
STOT RE 2; H373: 0.2 % ≤C < 1 %
STOT RE 2; H373: 0,2 % ≤C < 1 %
STOT RE 2 (*)
STOT RE 2 *
1; H31: 3 % ≤ C < 10 %
3 % ≤ C < 10 %
2; H319: 0,3 % ≤ C < 10 %
0,3 % ≤ C < 10 %
ammonia …. %
ammonia ….%
1B; H314: 5 % ≤ C < 20 %
1B; H314: 5 % ≤ C < 20 %
1B; H350: C ≥ 0,01 %
1B; H350: C ≥ 0,01 %
’amyl nitrite’, mixed isomers [2]
‘amyl nitrite’, mixed isomers [2]
hydrogen peroxide solution ... %
hydrogen peroxide solution … %
1; H271: C ≥ 70 %(****)
C ≥ 70 %****
2; H272: 50 % ≤ C < 70 %(****)
50 % ≤ C < 70 % ****
1B; H314: 50 % ≤ C < 70 %
1B; H314: 50 % ≤ C < 70 %
2; H315: 35 % ≤ C < 50 %
35 % ≤ C < 50 %
1; H318: 8 % ≤ C < 50 %
8 % ≤ C < 50 %
2; H319: 5 % ≤ C < 8 %
5 % ≤ C < 8 %
hydrofluoric acid ... %
hydrofluoric acid … %
1B; H314: 1 % ≤ C < 7 %
1B; H314: 1 % ≤ C < 7 %
2; H319: 0,1 % ≤ C < 1 %
0,1 % ≤ C < 1 %
2; H315: 10 % ≤ C < 25 %
10 % ≤ C < 25 %
1B; H314: 2 % ≤ C < 5 %
1B; H314: 2 % ≤ C < 5 %
2; H315: 0,5 % ≤ C < 2 %
0,5 % ≤ C < 2 %
sodium (n-butyl)x(ethyl)y-1,5-dihydro)aluminate x = 0.5 y = 1.5
sodium (n-butyl)x(ethyl)y-1,5-dihydro)aluminate x = 0,5 y = 1,5
α,ω-dihydroxypoly(hex-5-en-1-ylmethylsiloxane)hoxysilane with (hydrolysis product of silica and methyltrimethoxysilane)iazole
α, ω-dihydroxypoly(hex-5-en-1-ylmethylsiloxane)hoxysilane with (hydrolysis product of silica and methyltrimethoxysilane)iazole
STOT SE 2; H371: 0,2 % ≤ C < 1 %
STOT SE 2; H371: 0,2 % ≤ C < 1 %
parathion - methyl (ISO);
parathion — methyl (ISO);
O-2,4-dichlorophenyl O,O-diethyl phosphorothioate
O—2,4-dichlorophenyl O,O-diethyl phosphorothioate
GHS05
Dgr
Skin Corr.
1A; H314: C ≥ 15 % Skin Irrit.
2; H315: 5 % ≤ C < 15 % Eye Irrit.
5 % ≤ C < 15 %
2; H341: C ≥ 0.01 %
C ≥ 0,01 %
1B; H314: 10 % ≤ C < 50 %
1B; H314: 10 % ≤ C < 50 %
2; H315: 1 % ≤ C < 10 %
1 % ≤ C < 10 %
2; H319: 0,5 % ≤ C < 3 %
0,5 % ≤ C < 3 %
1B; H314: 5 % ≤ C < 10 %
1B; H314: 5 % ≤ C < 10 %
2; H315: 0,5 % ≤ C < 5 %
0,5 % ≤ C < 5 %
STOT SE 3; H335: 0,5 % ≤ C < 5 %
STOT SE 3; H335: 0,5 % ≤ C < 5 %
R43: C ≥ 0.5 %
C ≥ 0,5 %
Main component: acetoacetic acid anilide / 3-amino-1-hydroxybenzene (ATAN-MAP): trisodium 6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato-6''-[1-(phenylcarbamoyl)ethylazo]-5'''-(phenylsulfamoyl)-3''-sulfonatonaphthalene-2''-azobenzene-1'',2'''-diolatochromate (III);
Main component: acetoacetic acid anilide/3-amino-1-hydroxybenzene (ATAN-MAP): trisodium 6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato-6''-[1-(phenylcarbamoyl)ethylazo]-5'''-(phenylsulfamoyl)-3''-sulfonatonaphthalene-2''-azobenzene-1'',2'''-diolatochromate (III);
by-product 1: acetoacetic acid anilide / acetoacetic acid anilide (ATAN-ATAN): trisodium bis6-[1-(phenylcarbamoyl)ethylazo]-5'-(phenylsulfonyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolatochromate (III);
by-product 1: acetoacetic acid anilide/acetoacetic acid anilide (ATAN-ATAN): trisodium bis6-[1-(phenylcarbamoyl)ethylazo]-5'-(phenylsulfonyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolatochromate (III);
by-product 2: 3-amino-1-hydroxybenzene / 3-amino-1-hydroxybenzene (MAP-MAP): trisodium bis6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato chromate (III)
by-product 2: 3-amino-1-hydroxybenzene/3-amino-1-hydroxybenzene (MAP-MAP): trisodium bis6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato chromate (III)
zinc powder - zinc dust (pyrophoric)
zinc powder — zinc dust (pyrophoric)
zinc powder - zinc dust (stabilised)
zinc powder — zinc dust (stabilised)
oral
oral
dermal
dermal
fulminate of mercury [> 20 % phlegmatiser]
fulminate of mercury [≥ 20 % phlegmatiser]
lead azide [> 20 % phlegmatiser]
lead azide [≥ 20 % phlegmatiser]
butane (containing ≥ 0.1 % butadiene (203-450-8)); [1]
butane (containing ≥ 0,1 % butadiene (203-450-8)); [1]
isobutane (containing ≥ 0.1 % butadiene (203-450-8)) [2]
isobutane (containing ≥ 0,1 % butadiene (203-450-8)) [2]
1,2-bis[4-fluoro-6-4-sulfo-5-(2-(4-sulfonaphtalene-3-ylazo)-1-hydroxy-3,6-disulfo-8-aminonaphthalene-7-ylazo)phenylamino-1,3,5-triazin-2ylamino]ethane;x-sodium, y-potassium salts x = 7,755 y = 0,245
1,2-bis[4-fluoro-6-4-sulfo-5-(2-(4-sulfonaphtalene-3-ylazo)-1-hydroxy-3,6-disulfo-8-aminonaphthalene-7-ylazo)phenylamino-1,3,5-triazin-2ylamino]ethane; x-sodium, y-potassium salts x = 7,755 y = 0,245
α,α,α-trichlorotoluene;
α, α,α-trichlorotoluene;
α,α,α-trifluorotoluene;
α, α,α-trifluorotoluene;
α,α-dichlorotoluene;
α, α-dichlorotoluene;
3-chloro-4,5,α,α,α-pentafluorotoluene
3-chloro-4,5,α, α,α-pentafluorotoluene
α,α,α,4-tetrachlorotoluene;
α, α,α,4-tetrachlorotoluene;
2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)pent-4-en-2-ol
2-(2,4-dichlorophenyl)-1-(1H—1,2,4-triazol-1-yl)pent-4-en-2-ol
R-2,3-epoxy-1-propanol
R—2,3-epoxy-1-propanol
(±) trans-3,3-dimethyl-5-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-pent-4-en-2-ol
(±) trans—3,3-dimethyl-5-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-pent-4-en-2-ol
isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n=5 or 6
isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6
reaction mass of: 2-chloro-5-sec-tetradecylhydroquinones where sec-tetradecyl= 1-methyltridecyl;
reaction mass of: 2-chloro-5-sec-tetradecylhydroquinones where sec-tetradecyl = 1-methyltridecyl;
formaldehyde ... %
formaldehyde ...%
glyoxal... %;
glyoxal...%;
ethandial... %
ethandial...%
60 % anhydrous is equivalent to 70.4 % hydrate;
60 % anhydrous is equivalent to 70,4 % hydrate;
formic acid ... %
formic acid ... %
1A; H314: C ≥ 90 %
1A; H314: C ≥ 90 %
1B; H314: 10 % ≤ C < 90 %
1B; H314: 10 % ≤ C < 90 %
2; H315: 2 % ≤ C < 10 %
2 % ≤ C < 10 %
acetic acid ... %
acetic acid ... %
1B; H314: 25 % ≤ C < 90 %
1B; H314: 25 % ≤ C < 90 %
STOT SE 3; H335: C ≥ 1 %
STOT SE 3; H335: C ≥ 1 %
1B; H314: C ≥ 25 %
1B; H314: C ≥ 25 %
1; H318: 5 % ≤ C < 25 %
5 % ≤ C < 25 %
2; H319: 1 % ≤ C < 5 %
1 % ≤ C < 5 %
STOT SE 3; H335: C ≥ 5 %
STOT SE 3; H335: C ≥ 5 %
2; H315: C ≥ 5 %
C ≥ 5 %
1; H317: C ≥ 0,2 %
C ≥ 0,2 %
propionic acid ... %
propionic acid ... %
STOT SE 3; H335: C ≥ 10 %
STOT SE 3; H335: C ≥ 10 %
2; H319: C ≥ 1 %
C ≥ 1 %
methyl acrylamidomethoxyacetate (containing ≥ 0,1 % acrylamid)
methyl acrylamidomethoxyacetate (containing ≥ 0,1 % acrylamid)
methyl acrylamidoglycolate (containing ≥ 0,1 % acrylamide)
methyl acrylamidoglycolate (containing ≥ 0,1 % acrylamide)
poly(oxypropylenecarbonyl-co-oxy(ethylethylene)carbonyl), containing 27 % hydroxyvalerate
poly(oxypropylenecarbonyl-co-oxy(ethylethylene)carbonyl), containing 27 % hydroxyvalerate
reaction mass of: tetradecanoic acid (42,5-47,5 %);
reaction mass of: tetradecanoic acid (42,5-47,5 %);
poly(1-7)lactate esters of tetradecanoic acid (52,5-57,5 %)
poly(1-7)lactate esters of tetradecanoic acid (52,5-57,5 %)
reaction mass of: dodecanoic acid (35-40 %);
reaction mass of: dodecanoic acid (35-40 %);
poly(1-7)lactate esters of dodecanoic acid (60-65 %)
poly(1-7)lactate esters of dodecanoic acid (60-65 %)
reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2]
reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2]
lead styphnate (≥ 20 % phlegmatiser)
lead styphnate (≥ 20 % phlegmatiser)
STOT SE 2 (*) (*)
STOT SE 2 **
2; H319: 0,5 % ≤ C < 5 %
0,5 % ≤ C < 5 %
mono-methylamine ... %; [1]
mono-methylamine ... %; [1]
di-methylamine ... %; [2]
di-methylamine ... %; [2]
tri-methylamine ... % [3]
tri-methylamine ... % [3]
STOT RE 1; H372: C ≥ 1 %
STOT RE 1; H372: C ≥ 1 %
STOT RE 2; H373: 0,2 % ≤ C < 1 %
STOT RE 2; H373: 0,2 % ≤ C < 1 %
1A; H350: C ≥ 0,01 %
1A; H350: C ≥ 0,01 %
N,N,** TYPE="ITALIC">N',N'-tetramethyl-p-phenylenediamine
N,N,N',N'-tetramethyl-p-phenylenediamine
picramic acid (< 20 % water)
picramic acid (< 20 % water)
[≥ 20 % water]
[≥ 20 % water]
1B; H350: C ≥ 0,001 %
1B; H350: C ≥ 0,001 %
R33: C ≥ 0.1 %
C ≥ 0,1 %
Basic Violet 3 with ≥ 0,1 % of Michler's ketone (EC no. 202-027-5)
Basic Violet 3 with ≥ 0,1 % of Michler's ketone (EC no. 202-027-5)
EUH031: C ≥ 10 %
EUH031: C ≥ 10 %
1B; H314: C ≥ 50 %
1B; H314: C ≥ 50 %
2; H315: 30 % ≤ C < 50 %
30 % ≤ C < 50 %
1; H318: 15 % ≤ C < 50 %
15 % ≤ C < 50 %
2; H319: 5 % ≤ C < 15 %
5 % ≤ C < 15 %
1; H317: C ≥ 0,05 %
C ≥ 0,05 %
(5-bezylfur-3-yl)methyl(1R)-trans—2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboylate
(5-bezylfur-3-yl)methyl(1R)-trans-2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboylate
(R*, R*)-(±)-β-[(2,4-dichlorophenyl)methyl]-α-(1,1-dimethylethyl)-1H—1,2,4-triazole-1-ethanol;
(R*, R*)-(±)-β-[(2,4-dichlorophenyl)methyl]-α-(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol;
5,6-dihydro-3H-imidazo[2,1—c]-1,2,4-dithiazole-3-thione;
5,6-dihydro-3H-imidazo[2,1-c]-1,2,4-dithiazole-3-thione;
cis-4-[3-(p—tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine
cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine
2-(4-chlorophenyl)-2-(1H—1,2,4-triazol-1-ylmethyl)hexanenitrile
2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)hexanenitrile
1B; H314: C ≥ 0,6 %
1B; H314: C ≥ 0,6 %
2; H315: 0,06 % ≤ C < 0,6 %
0,06 % ≤ C < 0,6 %
1; H317: C ≥ 0,0015 %
C ≥ 0,0015 %
(RS)-2-(2,4-dichlorophenyl)-1-(1H—1,2,4-triazol-1-yl)hexan-2-ol
(RS)-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol
3-(2,4-dichlorophenyl)-6-fluoro-2-(1H—1,2,4-triazol-1-yl)quinazolin-4-(3H)-one
3-(2,4-dichlorophenyl)-6-fluoro-2-(1H-1,2,4-triazol-1-yl)quinazolin-4-(3H)-one
(±) 2-(2,4-dichlorophenyl)-3-(1H—1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether
(±) 2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether
(2RS,3SR)-3-(2-chlorophenyl)-2-(4-fluorophenyl)-[(1H—1,2,4-triazol-1-yl)methyl]oxirane
(2RS,3SR)-3-(2-chlorophenyl)-2-(4-fluorophenyl)-[(1H-1,2,4-triazol-1-yl)methyl]oxirane
Eye Irrit.; H319: C ≥ 5 %
Eye Irrit.; H319: C ≥ 5 %
Skin Sens.1; H317: C ≥ 0,5 %
Skin Sens.1; H317: C ≥ 0,5 %
1B; H360D: C ≥ 5 %
1B; H360D: C ≥ 5 %
5,6,12,13-tetrachloroanthra(2,1,9—def:6,5,10-d'e'f')diisoquinoline-1,3,8,10(2H,9H)-tetrone
5,6,12,13-tetrachloroanthra(2,1,9-def:6,5,10-d'e'f')diisoquinoline-1,3,8,10(2H,9H)-tetrone
N—tert-butyl-N'-(4-ethylbenzoyl)-3,5-dimethylbenzohydrazide
N-tert-butyl-N'-(4-ethylbenzoyl)-3,5-dimethylbenzohydrazide
reaction mass of: 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9—def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfonic acid;
reaction mass of: 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9-def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfonic acid;
potassium 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9—def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfate
potassium 2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1H,8H)-anthra[2,1,9-def: 6,5,10-d'e'f']diisoquinolin-2-ylethansulfate
N,N'—1,4-phenylenebis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamide
N,N'-1,4-phenylenebis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamide
1-[4-chloro-3-((2,2,3,3,3-pentafluoropropoxy)methyl)phenyl]-5-phenyl-1H—1,2,4-triazole-3-carboxamide
1-[4-chloro-3-((2,2,3,3,3-pentafluoropropoxy)methyl)phenyl]-5-phenyl-1H-1,2,4-triazole-3-carboxamide
(S)-N—tert-butyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide
(S)-N-tert-butyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide
1B; H314: C ≥ 10 %
1B; H314: C ≥ 10 %
1; H318: 3 % ≤ C < 10 %
3 % ≤ C < 10 %
2; H319: 1 % ≤ C < 3 %
1 % ≤ C < 3 %
STOT SE 3; H335: C < 10 %
STOT SE 3; H335: C < 10 %
[> 91 % solution]
[> 91 % solution]
[≤ 91 % solution]
[≤ 91 % solution]
O,O—tert-butyl O-docosyl monoperoxyoxalate
O,O-tert-butyl O-docosyl monoperoxyoxalate
reaction mass of: 1-methyl-1-(3-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide, 63 % by weight;
reaction mass of: 1-methyl-1-(3-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide, 63 % by weight;
1-methyl-1-(4-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide, 31 % by weight
1-methyl-1-(4-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxide, 31 % by weight
It consists of hydrocarbons having carbon numbers primarily in the range of C4 to C10 and distilling in the approximate range of 80 oC to 160 oC (175oF to 320oF).]
It consists of hydrocarbons having carbon numbers primarily in the range of C4 to C10 and distilling in the approximate range of 80 oC to 160 oC (175 oF to 320 oF).]
[The distillate from lignite tar boiling in the range of approximately 80 oC to 250 oC (176oF to 482oF).
[The distillate from lignite tar boiling in the range of approximately 80 oC to 250 oC (176 oF to 482 oF).
[The distillate from coke oven light oil having an approximate distillation range below 100 oC (212oF).
[The distillate from coke oven light oil having an approximate distillation range below 100 oC (212 oF).
Composed primarily of benzene, toluene and xylenes boiling in the range of approximately 75 oC to 200 oC (167oF to 392oF).]
Composed primarily of benzene, toluene and xylenes boiling in the range of approximately 75 oC to 200 oC (167 oF to 392 oF).]
It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C9 and boiling in the range of approximately 120 oC to 215 oC (248oF to 419oF).]
It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C9 and boiling in the range of approximately 120 oC to 215 oC (248 oF to 419 oF).]
[The redistillate from the distillate, freed of tar acids and tar bases, from bituminous coal high temperature tar boiling in the approximate range of 90 oC to 160 oC (194oF to 320oF).
[The redistillate from the distillate, freed of tar acids and tar bases, from bituminous coal high temperature tar boiling in the approximate range of 90 oC to 160 oC (194 oF to 320 oF).
It consists predominantly of unsubstituted and substituted mononuclear aromatic hydrocarbons boiling in the range of 85 oC-195 oC (185oF-383oF).]
It consists predominantly of unsubstituted and substituted mononuclear aromatic hydrocarbons boiling in the range of 85 oC-195 oC (185 oF-383 oF).]
[The first fraction from the distillation of aromatic hydrocarbons, coumarone, naphthalene and indene rich prefactionator bottoms or washed carbolic oil boiling substantially below 145 oC (293oF).
[The first fraction from the distillation of aromatic hydrocarbons, coumarone, naphthalene and indene rich prefactionator bottoms or washed carbolic oil boiling substantially below 145 oC (293 oF).
[The distillate from aromatic hydrocarbons, coumarone, naphthalene and indene rich prefractionator bottoms or washed carbolic oils, having an approximate boiling range of 155 oC to 180 oC (311oF to 356oF).
[The distillate from aromatic hydrocarbons, coumarone, naphthalene and indene rich prefractionator bottoms or washed carbolic oils, having an approximate boiling range of 155 oC to 180 oC (311 oF to 356 oF).
[The distillate from either high temperature coal tar, coke oven light oil, or coal tar oil alkaline extract residue having an approximate distillation range of 130 oC to 210 oC (266oF to 410oF) Composed primarily of indene and other polycyclic ring systems containing a single aromatic ring.
[The distillate from either high temperature coal tar, coke oven light oil, or coal tar oil alkaline extract residue having an approximate distillation range of 130 oC to 210 oC (266 oF to 410 oF) Composed primarily of indene and other polycyclic ring systems containing a single aromatic ring.
Composed primarily of alkyl-substituted one ring aromatic hydrocarbons boiling in the range of approximately 135 oC to 210 oC (275oF to 410oF).
Composed primarily of alkyl-substituted one ring aromatic hydrocarbons boiling in the range of approximately 135 oC to 210 oC (275 oF to 410 oF).
[This oil is a complex mixture of aromatic hydrocarbons, primarily indene, naphthalene, coumarone, phenol, and o-, m- and p-cresol and boiling in the range of 140 oC to 215 oC (284oF to 419oF).]
[This oil is a complex mixture of aromatic hydrocarbons, primarily indene, naphthalene, coumarone, phenol, and o-, m- and p-cresol and boiling in the range of 140 oC to 215 oC (284 oF to 419 oF).]
It consists of aromatic and other hydrocarbons, phenolic compounds and aromatic nitrogen compounds and distills at the approximate range of 150 oC to 210 oC (302oF to 410oF).]
It consists of aromatic and other hydrocarbons, phenolic compounds and aromatic nitrogen compounds and distills at the approximate range of 150 oC to 210 oC (302 oF to 410 oF).]
[The distillate from high temperature coal tar having an approximate distillation range of 130 oC to 250 oC (266oF to 410oF).
[The distillate from high temperature coal tar having an approximate distillation range of 130 oC to 250 oC (266 oF to 410 oF).
[The complex combination of polyalkylated pyridines derived from coal tar distillation or as high-boiling distillates approximately above 150 oC (302oF) from the reaction of ammonia with acetaldehyde, formaldehyde or paraformaldehyde.]
[The complex combination of polyalkylated pyridines derived from coal tar distillation or as high-boiling distillates approximately above 150 oC (302 oF) from the reaction of ammonia with acetaldehyde, formaldehyde or paraformaldehyde.]
[Pyridine bases boiling in the range of approximately 125 oC to 160 oC (257oF 320oF) obtained by distillation of neutralized acid extract of the base-containing tar fraction obtained by the distillation of bituminous coal tars.
[Pyridine bases boiling in the range of approximately 125 oC to 160 oC (257 oF 320 oF) obtained by distillation of neutralized acid extract of the base-containing tar fraction obtained by the distillation of bituminous coal tars.
[The distillation fraction boiling in the range of approximately 181 oC to 186 oC (356oF to 367oF) from the crude bases obtained from the neutralized, acid-extracted base-containing tar fractions obtained by the distillation of bituminous coal tar.
[The distillation fraction boiling in the range of approximately 181 oC to 186 oC (356 oF to 367 oF) from the crude bases obtained from the neutralized, acid-extracted base-containing tar fractions obtained by the distillation of bituminous coal tar.
[The distillation fraction boiling in the range of approximately 180 oC to 200 oC (356oF to 392oF) from the crude bases obtained by dephenolating and debasing the carbolated oil from the distillation of coal tar.
[The distillation fraction boiling in the range of approximately 180 oC to 200 oC (356 oF to 392 oF) from the crude bases obtained by dephenolating and debasing the carbolated oil from the distillation of coal tar.
It consists predominantly of indene and boils in a range of approximately 160 oC to 190 oC (320oF to 374oF).]
It consists predominantly of indene and boils in a range of approximately 160 oC to 190 oC (320 oF to 374 oF).]
[The redistillate obtained from the fractional distillation of bituminous coal high temperature tar and pyrolysis residual oils and boiling in the range of approximately 190 oC to 270 oC (374oF to 518oF).
[The redistillate obtained from the fractional distillation of bituminous coal high temperature tar and pyrolysis residual oils and boiling in the range of approximately 190 oC to 270 oC (374 oF to 518 oF).